Partnering With Ascentage

Leveraging our expertise in the field of protein-protein interactions, we are developing an innovative pipeline featuring small molecule candidates that target apoptotic pathways, as well as next-generation tyrosine kinase inhibitors with first- and best-in-class potential. We are committed to partnering with other complementary organizations that share our vision of bringing meaningful cures to patients with various cancers, hepatitis B, and age-related diseases.

For more information about partnering with Ascentage, please contact us at moc.a1571010451mrahp1571010451egatn1571010451ecsa@1571010451db1571010451.

 

Our Current Partnerships

In addition to our strong in-house research and development team, we have established global collaboration relationships with leading biotechnology and pharmaceutical companies and academic institutions, such as the University of Michigan, Unity, MSD, MD Anderson and Junshi Biosciences.

 

In April 2019, we entered into a clinical collaboration agreement with Junshi Bioscienceshas to explore the synergies of our IAP inhibitor, APG-1387, and Junshi Biosciences’ anti-PD-1 therapy, toripalimab, in clinical trials in solid and hematological tumors in China.

In October 2018, we entered into a strategic collaboration agreement with MD Anderson. Under the terms of the agreement, MD Anderson will conduct preclinical and clinical studies on APG-1252, APG-2575, APG-1387, APG-115, HQP1351, and other compounds under development by us.

Built upon a long-term academic relationship, we have established research collaborations and exclusive license agreements with the University of Michigan. Pursuant to the license agreement, the University of Michigan granted us an exclusive worldwide license to certain patent rights related to PPIs and apoptosis. Our academic collaboration with the University of Michigan enables us to tackle challenging therapeutic targets, gain access to the latest technologies, and enhance our preclinical and clinical studies capabilities, which allow us to accelerate our research and development progress substantially.

We have a strategic relationship with Unity pursuant to which Unity is exploring the development of molecules in our library of Bcl-2/Bcl-xL/McL-1 inhibitors for the treatment of age-related diseases. Through the collaboration with Unity, we are able to validate our patent portfolio with a library agreement, enhance our research capabilities and expand commercialization rights to global markets and additional therapeutic areas.

We entered into an agreement with Merck Sharp & Dohme to exclusively license certain technology and related patents covering HQP8361 (MK-8033), a c-Met targeting TKI in Australia, Japan and China.

 

Partnerships with Ascentage Pharma